Pomerantz Law Firm Investigates Evolus, Inc. Following FDA Warning Regarding Jeuveau Marketing
Pomerantz LLP has launched an investigation into Evolus, Inc. (NASDAQ: EOLS) following a warning letter from the U.S. Food and Drug Administration (FDA). The regulatory body flagged Instagram promotions for the company's wrinkle treatment, Jeuveau, as false or misleading due to improper comparisons with beauty products and the minimization of critical safety information. The FDA specifically objected to claims regarding the speed and completeness of results, noting that Evolus failed to adequately address boxed warnings concerning the distant spread of toxin effects. Following the disclosure of this warning on October 2, 2026, Evolus's stock price experienced a significant decline, falling 7.15% to close at $7.14 per share.
Tickers: $EOLS
Topics: Class Action Lawsuit FDA Warning Letter Misleading Advertising Securities Fraud Investigation
Read the full article at PR Newswire
Part of the story Pomerantz Law Firm Investigates EyePoint, Inc. Following Clinical Trial Failures (9 articles)